GlaxoSmithKline will no longer be manufacturing Zantac (ranitidine) 150mg and 300mg tablets, according to the Food and Drug Administration (FDA). The Company states that the product discontinuation is not related to the quality, safety, or efficacy of the product.
Specifically, the discontinued products include:
- Zantac 150mg tablets; 60-count bottles (NDC# 0173-0344-42)
- Zantac 300mg tablets; 30-count bottles (NDC# 0173-0393-40)
Zantac, an H2 receptor antagonist, is indicated for the short-term treatment of active duodenal ulcer; maintenance therapy for duodenal ulcer; pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome and systemic mastocytosis); short-term treatment of active, benign gastric ulcer; maintenance therapy for gastric ulcer; treatment of gastroesophageal reflux disease (GERD); treatment of endoscopically diagnosed erosive esophagitis; and maintenance of healing of erosive esophagitis.
Both the 150mg and 300mg strengths are available as generics; the 150mg strength is also available over-the-counter. GlaxoSmithKline states that the anticipated final date of availability for the 300mg strength tablets is July 31, 2018.
For more information visit GlaxoSmithKline.com.